Clinical trial
A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy.
NCT03570437 is registered in ClinicalTrials.gov with University of Manchester as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy.
- Lead sponsor
- University of Manchester
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 17, 2018
- Completion date
- June 30, 2023
- Enrollment
- 124 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.